Pakistan's brick kilns have often faced scrutiny over hazardous working conditions and exploitative child labour. Now, a fresh report has exposed a kidney racket targeting these desperate kiln workers.

Pakistan's Desperate Brick Kiln Workers Forced to Sell Kidneys, Report Says

India has made a leap to the 11th position in the ranking of the top direct seller markets with retail sales of $3.23 billion in 2022, according to a report by the international industry association World Federation of Direct Selling Associations (WFDSA).

The report by the WFDSA said that Indian direct selling has seen growth of 5.4 per cent above 2021 retail sales. According to the report, the Indian market experienced the highest Compounded Annual Growth Rate (CAGR) of nearly 13.3 per cent during the previous three years, measured in constant dollars.

The global direct selling market reported a 1.5 per cent fall to $172.89 billion in 2022.

With an overall decline of five&nbsp;per cent from 2021, the US ranked first on the list with $40.52. It was followed by Korea, Germany, China, Japan, and Malaysia.

According to Rajat Banerji, chairman of the India Direct Selling Association (IDSA), “India’s direct selling market is growing steadily and has the potential to place itself in the top five global markets over the next decade.”

He also added that the Consumer Protection (Direct Selling) Rules 202 and its subsequent amendment should bring stability to the Indian direct selling market, which may gather the interest of major international direct selling organisations as well as investors.

“Only three among the top ten (sellers) are in India today and we would like to see all start their business in India,” Rajat added.

IDSA is a self-regulatory body for the direct selling industry in India.

(With inputs form agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

India has made a leap to the 11th position in the ranking of the top direct seller markets with retail sales of $3.23 billion in 2022, according to a report by the international industry association World Federation of Direct Selling Associations (WFDSA).

India has made a leap to the 11th position in the ranking of the top direct seller markets with retail sales of $3.23 billion in 2022, according to a report by the international industry association World Federation of Direct Selling Associations (WFDSA). The report by the WFDSA said that Indian direct selling has seen growth of 5.4 per cent above 2021 retail sales. According to the report, the Indian market experienced the highest Compounded Annual Growth Rate (CAGR) of nearly 13.3 per cent during the previous three years, measured in constant dollars. The global direct selling market reported a 1.5 per cent fall to $172.89 billion in 2022. With an overall decline of five per cent from 2021, the US ranked first on the list with $40.52. It was followed by Korea, Germany, China, Japan, and Malaysia. According to Rajat Banerji, chairman of the India Direct Selling Association (IDSA), “India’s direct selling market is growing steadily and has the potential to place itself in the top five global markets over the next decade.” He also added that the Consumer Protection (Direct Selling) Rules 202 and its subsequent amendment should bring stability to the Indian direct selling market, which may gather the interest of major international direct selling organisations as well as investors. “Only three among the top ten (sellers) are in India today and we would like to see all start their business in India,” Rajat added. IDSA is a self-regulatory body for the direct selling industry in India. (With inputs form agencies) WATCH WION LIVE HERE

India moves up to 11th position in global direct selling ranking: Report

In a bid to make its medical products more accessible, US pharma giant Pfizer Inc. has decided to sell nearly two dozen patent-protected medicines and vaccines at not-for-profit prices to 45 low-income countries, the Wall Street Journal has reported.

Pfizer will begin shipping the medicines first to Ghana, Malawi, Rwanda, Senegal and Uganda before the end of this year, Chief Executive&nbsp;Albert Bourla told the US newspaper on Wednesday.

The company said that it is working with governments to improve their health-system infrastructure and resolve regulatory and procurement obstacles that often delay the arrival of drugs.

Among the 23 drugs that are being sent for almost a fraction of the cost are for cancer, heart conditions and autoimmune diseases.

The report suggests that the move to sell its medicines at a cheaper cost will help Pfizer build a potentially large new market for prescription drugs and vaccines and also earn goodwill with employees for philanthropic efforts.

It comes at a time when US pharma giants such as Pfizer, and Moderna have been facing criticism over pricing and for keeping monopoly control over vaccines and new Paxlovid pill.

Pfizer has made nearly $26bn in revenues in the first three months of 2022, the bulk from its COVID-19 vaccine and new pill to treat the virus, The Guardian reported.

The New York-based firm&nbsp;posted total sales&nbsp;of $25.7bn in the first quarter, up 77 per cent from a year earlier.

Pfizer has also voiced its opposition to sharing its intellectual property for medicines, saying that others would struggle to produce its mRNA vaccine – one of only two on the market. It said that “it is not as simple as sharing the ‘recipe’”.

(With inputs from agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

In a bid to make its medical products more accessible, US pharma giant Pfizer Inc. has decided to sell nearly two dozen patent-protected medicines and vaccines at not-for-profit prices to 45 low-income countries, the Wall Street Journal has reported.

In a bid to make its medical products more accessible, US pharma giant Pfizer Inc. has decided to sell nearly two dozen patent-protected medicines and vaccines at not-for-profit prices to 45 low-income countries, the Wall Street Journal has reported. Pfizer will begin shipping the medicines first to Ghana, Malawi, Rwanda, Senegal and Uganda before the end of this year, Chief Executive Albert Bourla told the US newspaper on Wednesday. The company said that it is working with governments to improve their health-system infrastructure and resolve regulatory and procurement obstacles that often delay the arrival of drugs. Among the 23 drugs that are being sent for almost a fraction of the cost are for cancer, heart conditions and autoimmune diseases. The report suggests that the move to sell its medicines at a cheaper cost will help Pfizer build a potentially large new market for prescription drugs and vaccines and also earn goodwill with employees for philanthropic efforts. It comes at a time when US pharma giants such as Pfizer, and Moderna have been facing criticism over pricing and for keeping monopoly control over vaccines and new Paxlovid pill. Pfizer has made nearly $26bn in revenues in the first three months of 2022, the bulk from its COVID-19 vaccine and new pill to treat the virus, The Guardian reported. The New York-based firm posted total sales of $25.7bn in the first quarter, up 77 per cent from a year earlier. Pfizer has also voiced its opposition to sharing its intellectual property for medicines, saying that others would struggle to produce its mRNA vaccine – one of only two on the market. It said that “it is not as simple as sharing the ‘recipe’”. (With inputs from agencies) WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Amid criticism of Covid profiteering, Pfizer to sell vaccines, drugs at lower prices to poor nations

SoftBank Group Corp said on Wednesday it is selling its roughly 20 percent stake in Indian e-commerce firm Flipkart to Walmart Inc.

Walmart said earlier this month it will pay <a href="http://www.wionews.com/business-%26-economy/walmart-buying-77-stake-in-flipkart-for-16-billion-135737">$16 billion</a> for a roughly 77 percent stake in Flipkart, the US&nbspretailer's largest-ever deal.

A SoftBank spokesman declined to give further details.

SoftBank CEO Masayoshi Son said earlier this month the $2.5 billion investment through its private equity fund in Flipkart made last year was worth $4 billion. 
&nbsp

Walmart said earlier this month it will pay $16 billion for a roughly 77 percent stake in Flipkart. SoftBank owns an about 20% stake in Flipkart

SoftBank Group Corp said on Wednesday it is selling its roughly 20 percent stake in Indian e-commerce firm Flipkart to Walmart Inc. Walmart said earlier this month it will pay $16 billion for a roughly 77 percent stake in Flipkart, the US&nbspretailer's largest-ever deal. A SoftBank spokesman declined to give further details. SoftBank CEO Masayoshi Son said earlier this month the $2.5 billion investment through its private equity fund in Flipkart made last year was worth $4 billion.

SoftBank says selling entire Flipkart stake to Walmart

selling

Selling, News on Selling, stories on Selling, articles on Selling, Selling stories at Wion, Selling news, Selling latest news